Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
How we make money
Peptide Association LLC is a for-profit company. You should know who pays us before you take our word for anything.
Most organisations with “Association” in the name are trade bodies: they represent practitioners, and their members are the professionals. We are the other kind. Our members are the people using peptide therapy. Physicians and pharmacies are partners who serve those members.
We are not an accrediting body, a licensing board, or a government-affiliated organisation. We cannot claim to be independent either, because we are paid by providers we refer to. What we can do is show you the whole arrangement and let you weigh it.
Every way we earn
Referral compensation
Carries a conflictWe receive compensation from the clinical providers we route patients to, including when you book or become a patient. This is disclosed next to every link that sends you to a provider, at the same size as the surrounding text.
Memberships
Aligned with membersMembers pay us directly for access to the protocol library, education, and research summaries. Member dues are paid by members, so they are the part of our revenue that answers only to members.
Sponsorships
Aligned with membersPharmacies, suppliers, labs and software vendors pay flat quarterly fees for named placements. Set in advance, never tied to the volume or value of any patient referral, and never able to buy clinical placement.
The honest reading of that table: referral compensation is the line with a built-in conflict, because we are paid when you become someone's patient. We are deliberately growing the two lines that are not paid per patient. You are entitled to hold us to that.
What we have refused to sell
Promises are cheap. These are decisions that cost us revenue, and you can verify each one on the site.
We removed the retatrutide purchase path
Retatrutide is investigational, has no lawful US compounding pathway, and we were marketing access to it. We deleted the acquisition section and kept the published research. The page still gets traffic; it no longer converts.
We turned off the consultation button on 168 of 265 compound pages
A consultation or pharmacy link now appears only where a compound is FDA-approved or lawfully compoundable under 503A. Every other compound profile shows its regulatory status instead of a way to buy. That was the majority of our compound pages.
We took the Outcomes Registry offline
It advertised the largest real-world peptide outcomes dataset in existence. The dataset did not exist yet, so the pages now return a 410 rather than collect sign-ups against a claim we could not support.
We stopped calling ourselves an accrediting body
We are not one. We removed the certification product, the credentialing language, and the verified-provider badge claims. We review licensure against the CMS registry; we do not license, credential, or accredit anyone.
We removed our own countdown timers
Manufactured scarcity on health decisions is manipulation. If a real limit exists — like one sponsor per category per quarter — we will tell you the actual number. If there is no limit, we will not invent one.
Holding us to it
If you find a claim on this network you think we cannot support, tell us and we will either source it or remove it. That is the same standard we applied to our own pages, and several of them did not survive it.
Read our editorial policy for how content is researched and reviewed, or contact us directly. Companies interested in flat-fee placements can read the terms on our sponsorship page.